高剂量的乙氨基作为治疗癌症的治疗方法
Jeffrey Wu1, Bradley Maller2,3, Rujul Kaul2
1Department of Neurology, School of Medicine, Oregon Health and Sciences University, 3181 Sam Jackson Park Rd., Portland, OR 97239, USA.
高剂量的乙氨基 (AAP) 通过独立于自由基的新机制显示出抗瘤功效. 将AAP与fomepizole和n-乙半氨酸 (NAC) 结合起来,可以为癌症治疗提供更高,无毒的剂量.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 免疫学 免疫学 免疫学
背景情况:
- 高剂量的乙氨基 (AAP) 与n-乙半氨酸 (NAC) 救援已经显示出早期的承诺作为一种抗癌疗法.
- 现有研究表明,AAP的抗瘤作用可能独立于与已知的肝毒性相关的自由基机制.
研究的目的:
- 研究高剂量AAP抗瘤活性的新型,自由基独立的机制.
- 在临床前癌症模型中评估高剂量AAP与fomepizole和NAC结合的疗效和安全性.
主要方法:
- 进行了第一阶段试验和相关分析.
- 反向翻译研究发现了涉及JAK-STAT信号调制的机制.
- 临床前研究在小鼠模型中使用高剂量的AAP与fomepizole和NAC.
主要成果:
- 高剂量的AAP通过独立于自由基的机制表现出抗瘤功效.
- 新的机制包括调节瘤细胞和免疫微环境中的JAK-STAT信号.
- 同时使用AAP,fomepizole和NAC,在没有毒性的小鼠中达到100倍以上的AAP水平,在耐标准治疗的肺癌和乳腺癌模型中显示出有效性.
结论:
- 高剂量的AAP通过新的,自由基独立的途径表现出强大的抗瘤活性.
- 将AAP与fomepizole和NAC相结合,可以获得显著更高的,无毒的治疗水平.
- 需要进一步的临床试验来探索这种组合作为潜在的癌症治疗方法.
更多相关视频
13:38Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells
Published on: January 18, 2017
19:44Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen
Published on: May 30, 2012
相关概念视频
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
Two synthetic agonists of THC,...
Tumor Immunotherapy
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
